Market capitalization | $12.44m |
Enterprise Value | $-8.74m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.57 |
EV/Sales (TTM) EV/Sales | -4.72 |
P/S ratio (TTM) P/S ratio | 6.72 |
P/B ratio (TTM) P/B ratio | 1.13 |
Revenue growth (TTM) Revenue growth | 141.46% |
Revenue (TTM) Revenue | $1.85m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
2 Analysts have issued a Longeveron Inc - Ordinary Shares - Class A forecast:
2 Analysts have issued a Longeveron Inc - Ordinary Shares - Class A forecast:
Sep '24 |
+/-
%
|
||
Revenue | 1.85 1.85 |
140%
140%
|
|
Gross Profit | 0.40 0.40 |
151%
151%
|
|
EBITDA | -17 -17 |
16%
16%
|
EBIT (Operating Income) EBIT | -18 -18 |
15%
15%
|
Net Profit | -18 -18 |
10%
10%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Longeveron LLC is a clinical stage biotechnology company that engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. The company was founded by Joshua M. Hare and Donald M. Soffers in October 9, 2014 and is headquartered in Miami, FL.
Head office | United States |
CEO | Mohamed Hashad |
Employees | 25 |
Founded | 2014 |
Website | www.longeveron.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.